First PREMIER Bank Sells 3,573 Shares of Bristol-Myers Squibb (NYSE:BMY)

First PREMIER Bank decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,757 shares of the biopharmaceutical company’s stock after selling 3,573 shares during the period. First PREMIER Bank’s holdings in Bristol-Myers Squibb were worth $280,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaMark Advisors LLC boosted its holdings in Bristol-Myers Squibb by 73.7% in the 2nd quarter. AlphaMark Advisors LLC now owns 39,266 shares of the biopharmaceutical company’s stock valued at $1,631,000 after purchasing an additional 16,661 shares during the period. Baader Bank Aktiengesellschaft bought a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $260,000. Country Club Bank grew its position in Bristol-Myers Squibb by 1.7% during the second quarter. Country Club Bank now owns 36,469 shares of the biopharmaceutical company’s stock worth $1,514,000 after buying an additional 608 shares in the last quarter. Keudell Morrison Wealth Management increased its stake in Bristol-Myers Squibb by 29.1% during the 2nd quarter. Keudell Morrison Wealth Management now owns 21,245 shares of the biopharmaceutical company’s stock worth $882,000 after acquiring an additional 4,793 shares during the period. Finally, AdvisorNet Financial Inc raised its holdings in Bristol-Myers Squibb by 6.2% in the 2nd quarter. AdvisorNet Financial Inc now owns 35,452 shares of the biopharmaceutical company’s stock valued at $1,472,000 after acquiring an additional 2,073 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BMY shares. Deutsche Bank Aktiengesellschaft reduced their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. TD Cowen raised their target price on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday. BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Finally, Barclays downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective for the company. in a research report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $54.86.

Bristol-Myers Squibb Trading Up 1.5 %

Shares of NYSE:BMY traded up $0.71 during midday trading on Thursday, hitting $49.12. 13,138,892 shares of the stock were exchanged, compared to its average volume of 15,915,160. The business’s 50-day moving average price is $43.58 and its 200 day moving average price is $46.61. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.41. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock has a market capitalization of $99.57 billion, a price-to-earnings ratio of -15.85, a P/E/G ratio of 12.51 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.75 EPS. Analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.89%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.